Clinical Trial Search

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042

Primary: Overall Survival in Lymph Nodes Examined Patients — NA; NA years — p=0.007

Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months

Primary: Safety: Number of Participants With Freedom From Device and Procedure-related Major Adverse Events — 18 Participants — p=0.1309

Primary: The Patient Clinical Profile (General Clinical Data and Breast Cancer Characteristics) — 63.5; 48.8; 84.1; 41.1 percentage of participants

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Progression-free Survival — 11.2 months

Primary: Sentinel Lymph Node Positivity — 2 Participants

Primary: Overall Tumor Response — 1; 8; 14; 9 participants

Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36

Primary: Time to Next Treatment (TNT) — 26.7 months

Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients

Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants

Primary: Tumor Response — 0; 0 participants

Primary: Objective Response Rate — 0.09 proportion of participants

Primary: Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products — 9 participants

Primary: Time to Treatment Failure (TTF) Compared Between Treatment Groups. — 5.7; 8.3 months

Primary: Local Tumor Control for Each Index Tumor as Measured by Imaging at Month 12 — 84.6 percentage of tumors — p=0.410

Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001

Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05

Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response

Primary: Cancer Detection Performance of FACBC PET/CT — 17; 22; 4; 14 Participants

Primary: Number of Participants With Progression Free Survival (PFS) — 9; 19; 6; 10 Participants

Primary: Objective Response Rate — 10.7; 15.0; 25.0; 0.0 percentage of participants — p=0.94

Primary: Local Tumor Control for Each Index Tumor as Measured by Imaging at Month 60 — 80.0; 45.0; 15.0; 20.0 percentage of tumors

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events…

Primary: Maximum Tolerated Dose (MTD) of Hypofractionated Radiosurgery Defined as the Highest Dose Level Where a Grade 3 or Greater With an Attribution Score of ≥ 3 Develops in ≤…

Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient